<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 22 Oct 2026 13:30:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[TransCode Therapeutics (NASDAQ: RNAZ)]]></title>
      <link>https://www.redchip.com/webinar/RNAZ/81817787778</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/RNAZ/81817787778</guid>
      <pubDate>Wed, 16 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[TransCode Therapeutics is a clinical-stage oncology company developing a differentiated portfolio of RNA therapeutics, cancer vaccines, and immuno-oncology therapies designed to address advanced and metastatic cancers. The Company's proprietary nanoparticle delivery platform is engineered to overcome one of the greatest challenges in RNA medicine—efficiently delivering therapeutics directly to tumors beyond the liver—potentially enabling more precise treatment of metastatic disease. TransCode's lead candidate, TTX-MC138, has demonstrated encouraging clinical safety, evidence of tumor-targeted delivery in humans, and promising early efficacy, while advancing into a Phase 2a trial targeting minimal residual disease in colorectal cancer. Supported by technology developed at Harvard Medical School and Massachusetts General Hospital, TransCode has built a diversified oncology pipeline with multiple clinical and preclinical programs, creating several opportunities for value creation through upcoming clinical milestones and potential strategic partnerships.]]></description>
    </item>
    <item>
      <title><![CDATA[FibroBiologics (NASDAQ: FBLG)]]></title>
      <link>https://www.redchip.com/webinar/FBLG/85780019692</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/FBLG/85780019692</guid>
      <pubDate>Tue, 22 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[FibroBiologics is a clinical-stage biotechnology company developing allogeneic, fibroblast-based cell therapies to address chronic diseases with large unmet needs. Its novel approach leverages the regenerative, immunomodulatory, and scalable properties of fibroblasts—offering a practical alternative to stem cell therapies. The company’s lead program, CYWC628, targets diabetic foot ulcers and is expected to enter a Phase 1/2 clinical trial in Australia in 2025. Additional candidates include CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis. Backed by over 270+ patents and a growing body of supportive preclinical data, FibroBiologics is advancing a platform with broad therapeutic potential across wound healing, neurodegeneration, and autoimmune conditions. With experienced leadership, strong IP, and near-term clinical catalysts, FibroBiologics offers investors early access to a differentiated, scalable cell therapy platform poised to disrupt multi-billion-dollar markets.]]></description>
    </item>
    <item>
      <title><![CDATA[BioVie]]></title>
      <link>https://www.redchip.com/webinar/BIVI/82953743983</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BIVI/82953743983</guid>
      <pubDate>Wed, 23 Sep 2026 15:00:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[New Horizon Aircraft]]></title>
      <link>https://www.redchip.com/webinar/HOVR/89061326027</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/HOVR/89061326027</guid>
      <pubDate>Wed, 23 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Clinch Resources]]></title>
      <link>https://www.redchip.com/webinar/CLCH/86427547349</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/CLCH/86427547349</guid>
      <pubDate>Thu, 24 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[60 Degrees Pharmaceuticals]]></title>
      <link>https://www.redchip.com/webinar/SXTP/83874994795</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/SXTP/83874994795</guid>
      <pubDate>Tue, 29 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[First Phosphate (NASDAQ: PHOS)]]></title>
      <link>https://www.redchip.com/webinar/PHOS/88442329667</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/PHOS/88442329667</guid>
      <pubDate>Thu, 01 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[First Phosphate is an advanced-stage critical minerals company developing a vertically integrated North American supply of high-purity phosphate for the lithium iron phosphate (LFP) battery market. The Company’s flagship Bégin-Lamarche project in Quebec hosts a large-scale igneous phosphate resource uniquely suited to producing purified phosphoric acid (PPA), a critical precursor for LFP cathode materials. With a strategy spanning mining, processing and downstream battery materials, First Phosphate is positioned to help establish a secure Western supply chain for the rapidly growing LFP battery industry.]]></description>
    </item>
    <item>
      <title><![CDATA[Edge Total Intelligence (OTCQB: UNFYF)]]></title>
      <link>https://www.redchip.com/webinar/UNFYF/84306527959</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/UNFYF/84306527959</guid>
      <pubDate>Tue, 06 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[edgeTI™ provides operational intelligence software and solutions for defense, maritime, manufacturing, critical infrastructure and government organizations whose systems by design cannot be consolidated. Its edgeCore™ platform creates a unified, real-time operational picture and enables governed action across those systems, with approvals, controls and evidence preserved. Customer data remains in place and under the customer's control. Having attained Technology Readiness Level 9, edgeTI solutions have been authorized to operate and deployed in classified environments. edgeTI is headquartered in Arlington, Virginia, with operations in the United States, Canada, Australia and Serbia.]]></description>
    </item>
    <item>
      <title><![CDATA[Nova Minerals Corp.]]></title>
      <link>https://www.redchip.com/webinar/NVA/83073728095</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NVA/83073728095</guid>
      <pubDate>Wed, 07 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Exyn Technologies]]></title>
      <link>https://www.redchip.com/webinar/EXYN/87837866243</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/EXYN/87837866243</guid>
      <pubDate>Thu, 08 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Nexalin Technology]]></title>
      <link>https://www.redchip.com/webinar/NXL/88046611977</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NXL/88046611977</guid>
      <pubDate>Mon, 12 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.]]></description>
    </item>
    <item>
      <title><![CDATA[ASP Isotopes]]></title>
      <link>https://www.redchip.com/webinar/ASPI/89403250350</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ASPI/89403250350</guid>
      <pubDate>Tue, 13 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Noble Africa]]></title>
      <link>https://www.redchip.com/webinar/NDRA/83554432651</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NDRA/83554432651</guid>
      <pubDate>Thu, 15 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Anixa Biosciences (NASDAQ: ANIX)]]></title>
      <link>https://www.redchip.com/webinar/ANIX/83349309450</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ANIX/83349309450</guid>
      <pubDate>Tue, 20 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.]]></description>
    </item>
    <item>
      <title><![CDATA[Powering the Future: The Next Generation of Energy Infrastructure]]></title>
      <link>https://www.redchip.com/webinar/redchip/81805443130</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/81805443130</guid>
      <pubDate>Thu, 22 Oct 2026 13:30:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
  </channel>
</rss>
